EISAI PRESENTS LATEST PHASE I/II DATA ON
IN-HOUSE DEVELOPED ANTI-FRACTALKINE ANTIBODY E6011
RESULTS SUGGEST SAFETY, TOLERABILITY AS WELL AS CLINICAL ACTIVITY
IN RHEUMATOID ARTHRITIS AND CROHN’S DISEASE
June 13, 2016
Eisai Co., Ltd. (“Eisai”) put out today the following press release about E6011, which Eisai has developed jointly with its gastrointestinal area subsidiary EA Pharma Co., Ltd.
For full text of the press release, please see the URL below in the website of Eisai Co., Ltd.
EA pharma Co., Ltd.
Corporate Planning Dept.